Abstract Interleukin 9 secreting T H 9 cells have been proposed as the latest addition to the family of T helper cell subsets. While a growing body of evidence from animal models points to important roles for these cells in allergic inflammation of the lung, autoinflammation of the gastrointestinal tract, and tumor immunity, their role in skin immunity and skin immunopathology remains poorly defined. Interestingly, studies of T helper cells from healthy humans suggest that T H 9 cells are predominantly skin-homing and skin-resident and that they are involved in protection against extracellular pathogens. Thus, T H 9 cells have entered the stage as potential mediators of cutaneous pathology. However, under which conditions and by which mechanisms these cells contribute to skin immunity and disease still has to be investigated. Here, we review our current understanding of T H 9 cells as skin-tropic T helper cells and their involvement in skin pathology. Further, we discuss open questions with regard to the intricate nature of interleukin 9 producing T helper cells.
Introduction
Interleukin 9 secreting T H 9 cells are the latest addition to the growing family of T helper cells. Since the description of T H 9 cells in 2008, important progress has been made in the understanding of the cellular identity, transcriptional regulation, and functional importance of these cells [1] . Besides their welldescribed functions in immunopathology of the lung and the gut, an increasing body of evidence suggests that these cells play important roles in skin immunity, both in health and disease. Furthermore, the discovery of the superior capacity of T H 9 cells to mediate tumor immunity to the skin cancer melanoma has moved these cells into the limelight of cutaneous tumor immunology. In this review, we describe the insights into the functional role of Th9 cells in skin immunity and immunopathology that have been gained since their discovery as putative novel T helper cell subset and we discuss important open questions that will have to be addressed in future studies of cutaneous Th9 biology.
Unanswered questions regarding T H 9 cells in skin disorders
As in diseases of other tissues and organs, the role of T H 9 cells in skin disorders remains incompletely understood. The available data originates from a limited number of mouse models or correlative studies in humans, making the interpretation of the functional role of cutaneous IL-9 producing T H cells inconclusive [1] . In addition, the existence of a bona fide T H 9 cell as a distinct T helper cell subset in skin immunity has formally not been proven. To date, there is no unequivocal data showing stable IL-9 production in T helper cells which are distinct from one of the already defined T H cell subsets. In fact, the BT H 9^phenotype appears to be transient in vitro [2] in most disease models [3] [4] [5] , and in vivo in humans [6] . Similar to its transient expression in T cells, IL-9 is also only transiently expressed after activation by innate lymphoid cells, the putative evolutionary precursors of T cells [7, 8] . In addition, the cytokine co-expression profiles in IL-9 producing T H cells has not been systematically evaluated over time on a single-cell level [7, 9] , and a transcription factor that serves as master gene regulator of T H 9 cells still awaits identification. Therefore, it has been proven challenging to unambiguously identify T H 9 cells in the skin and differentiate them from other T H cell subsets with the ability to secrete IL-9. These limitations have to be taken into account when reviewing the role of T H 9 cells in skin disorders. For ease of readability in this article, however, cells with an IL-9 secreting phenotype will be termed T H 9 cells, regardless of the stability of IL-9 production or cytokine co-expression profiles of these cells. Delineating the true existence of a T H 9 lineage is currently the subject of intensive study for which models of cutaneous inflammation and immunity will certainly function as important tools [9] .
T H 9 cells in skin immunity

Th9 cells in skin infection
Studies of tissue-homing and tissue-resident human memory T cells suggest that there is a close link between skin immunity and T H 9 cells [2, 10, 11] . Analysis of T cells from human blood and tissues revealed that T H 9 cells were predominantly skin-tropic or skin-resident [2, 11] . In vivo primed memory T H cells of healthy donors expressing the major skin-homing receptor cutaneous lymphocyte antigen (CLA) were highly enriched for T H 9 cells, whereas gut-homing T cells, identified by their expression of α4β7, contained only very few T H 9 cells. CLA on T cells enables them to bind to and roll along endothelium expressing E-selectin. This tethering is crucial for T cells to enter both inflamed and normal skin and thus CLA is regarded as the major skin-homing receptor of T cells together with chemokine receptor 4 (CCR4) [12] . In these skin-tropic T H cells, IL-9 production was transiently expressed after activation and preceded the upregulation of other inflammatory cytokines. In contrast to these data, T cells from peripheral blood which are polarized in vitro under T H 9-inducing conditions have been shown to express the guthoming integrins α4 and β7 [13] . This discrepancy might be explained by the fact that T H cells which were primed in vivo might differ in terms of their cytokine profile and tissuehoming receptor repertoire from T cells primed in vitro [14] . Future studies are thus needed to define the conditions which regulate homing of T H 9 cells into different tissues in health and disease.
Furthermore, antigen-specificity studies of in vivo differentiated T H cells revealed that many IL-9 producing T H cells are specific for Candida albicans [2] . These C. albicans specific T H cells showed transient expression of IL-9 without coproduction of IL-17, thus showing distinctness from T H 17 cells, the T H subset known to be crucial in immunity against C. albicans [14, 15] . Together, these findings indicate that T H 9 cells play a critical role in the cutaneous defense against extracellular pathogens in healthy individuals. The mechanism, however, by which T H 9 cells participate in the cutaneous immune response to extracellular microbes remains speculative as neither data from human skin infections nor from mouse models are available. Nevertheless, it is possible that, in the context of fungal skin infection, T H 9 cells are induced via TGF-β and IL-4 secreted by keratinocytes and antigenpresenting cells (APCs) which were activated via pathogenrecognition receptors. For instance, in monocytes and macrophages, Candida-derived β-glucans bind to toll-like receptor (TLR) 2/6 and induce TGF-β secretion whereas chitin induces IL-4 secretion thus providing the key differentiation cytokines for T H 9 cells [16] . Thereafter, T H cell derived IL-9 might be important for rapid activation of innate immune cells, such as mast cells, neutrophils, and eosinophils, on the one hand, and of keratinocytes on the other hand ( Fig. 1 , putative role of T H 9 cells in skin immunity).
First, IL-9 is a key activator and survival factor of mast cells, and T H 9 cells have been shown to be critical for tissue mast cell accumulation and activation [17, 18] . In mast cells, IL-9 induces the secretion of proinflammatory mediators such as IL-6 and TNF-α, both of which are important for mounting effective anti-fungal immune responses [19] [20] [21] . Activated mast cells are specifically able to kill C. albicans [17, [22] [23] [24] . In some tumor models, T H 9-mediated anti-melanoma immunity is mast cell dependent [10] . Thus, given the abundance of mast cells in human skin, their capacity to produce potent proinflammatory mediators in response to IL-9, and the striking skin-tropism of T H 9 cells, it appears likely that mast cells are important effector cells through which T H 9 cells exert their function in cutaneous immunity against fungi. Second, also eosinophils may exert effector functions in the T H 9-mediated cutaneous immune response to C. albicans, albeit their exact role in anti-fungal immune responses is less well understood. Nevertheless, under distinct circumstances, eosinophils have been shown to play a role in anti-fungal skin immunity [25] . Since IL-9 can induce tissue influx, activation, and survival of eosinophils, it appears possible that they too are effectors of T H 9-mediated skin immunity [25] [26] [27] [28] . Finally, T H 9 cells may also attract neutrophils to infected skin via activation of the epithelium. Namely, IL-9 induces the secretion of IL-8 in keratinocytes and thereby the influx of neutrophils which are key effector cells against fungal skin infections [19, 29, 30] . IL-9 is then able to activate these neutrophils and renders them resistant to apoptosis under inflammatory conditions [13] . In summary, rapid and transient secretion of IL-9 by C. albicans specific skin-resident T H 9 cells might function to bridge the adaptive and the innate immune response to common fungal skin infections. The conditions under which this occurs and the precise mechanisms, however, still await elucidation.
T H 9 cells as skin-resident T cells
In accordance with the predominant skin-homing phenotype of circulating human T H 9 cells, IL-9 secreting T H cells were also found in the skin-resident population of healthy humans but not in T cells isolated from the healthy gut or lung [2] . These findings were recently confirmed by mass cytometry analysis of T H cells isolated from multiple human tissues [11] . As their circulating skin-homing counter parts, skin-resident T H cells produce IL-9 transiently post activation and this precedes the upregulation of other T H cell subset defining cytokines. IL-9 secreted from skin-tropic T H cells was also found to enhance cytokine production from other T cell subsets, suggesting one function of IL-9 may be the rapid and broad amplification of inflammation [2] .
The skin-residency of human T H 9 cells under non-inflamed conditions was somewhat unexpected since, in mouse models and some human diseases, T H 9 cells have mainly been linked to allergic inflammation of the lung and autoinflammation of the gut [31] [32] [33] [34] [35] . It remains to be investigated if under inflammatory conditions in humans, tissue-homing patterns are altered in a way that enables T H 9 cells to home to other peripheral organs, which would help explain this discrepancy.
Howsoever, the close association between skin-resident T cells and the T H 9 cells might be explained by the role of transforming growth factor-β (TGF-β) in the development of both of these cell types. TGF-β is expressed in the skin epithelium and is central in promoting both the T H 9 phenotype and skin-residency of T cells [36] [37] [38] [39] [40] . For the development of long-lived skin-resident memory T cells, TGF-β is essential by driving the upregulation of CD103 (also known as αE, which pairs with the β7 integrin chain). CD103 on T cells binds to E-cadherin on keratinocytes and is thought to be crucial for their retention in the skin [36, 40] . In T H 9 development, TGF-β together with IL-4 drives the T H 9 phenotype in differentiating naïve T cells [35, 36] and is able to induce IL-9 production in memory T H 2 and T H 17 cells [38, 39, 41] . Since skin-resident T cells differentiate and accumulate in the skin as a result of cutaneous infections, it is likely that under the TGF-β-rich environment of the skin, pathogenspecific T cells infiltrating the skin in the course of infection can acquire both the skin-resident phenotype and the ability to produce IL-9 [42] . It will be interesting to study the tissuehoming and tissue-residency pattern of human T H 9 cells under pathological skin conditions to further unravel this close relationship between cutaneous immunity and T H 9 cells.
Th9 cells in skin disorders
The majority of published reports and studies on the role of T H 9 cells in skin disorders is related to T H 2-mediated and allergic inflammation, most notably atopic dermatitis and allergic contact dermatitis. In addition, a growing body of evidence from mouse models points to a superior role of T H 9 cells in the mediation of tumor immunity against the skin cancer melanoma (reviewed elsewhere). There are also reports suggesting a role of T H 9 cells in other inflammatory and neoplastic disorders of the skin, such as psoriasis and cutaneous T cell lymphoma, respectively.
T H 9 cells in atopic dermatitis
Before the first description of T H 9 cells in 2008, little was known about the contribution of IL-9 and T H 9 cells to atopic dermatitis [38, 39] . At that time, IL-9 was mostly studied in the context of helminth infections and allergic lung inflammation. After the description of T H 9 cells, however, a number of studies addressed the role of IL-9 in allergic AD. These studies provide evidence for increased expression of IL-9 in atopic dermatitis, both in pediatric patients and in adults [43] [44] [45] . In these patients, IL-9 levels correlated with clinical severity, IgE levels, and CCL17 levels, indicating an intimate relationship of IL-9 with classical mediators of T H 2-induced inflammation [44] . Interestingly, IL-9 expression was shown to be amongst the earliest cytokines to be upregulated in acute canine atopic dermatitis, nicely fitting to the early expression kinetics of IL-9 observed post activation of skin-tropic T H cells [2, 46] . A potential pathogenic role of IL-9 in atopic dermatitis is indicated by the discovery of a significant association between IL-9 and IL-9 receptor gene polymorphisms and atopic dermatitis in the Korean population [47] . The mechanisms by which IL-9 contributes to AD as well as the cellular sources of IL-9 in AD lesions are incompletely understood. Nevertheless, a few mediators of T H 9-driven inflammation in atopic dermatitis have been identified. For instance, Itk, a mediator of T cell receptor signaling and a positive regulator of T H 9 differentiation, has been shown to be expressed in T cells in lesional skin of AD but not in psoriasis [48, 49] . As for the downstream effects of IL-9 in atopic dermatitis, similar considerations can be made as have been outlined above for their role in skin infection (Fig. 2) . IL-9 promotes tissue accumulation, survival, and activation of mast cells, eosinophils, and innate lymphoid cells, all of which are key cellular contributors to atopic dermatitis pathogenesis [50] . In particular, IL-9 seems to play an important role in early activation of ILCs, in which it enhances the secretion of IL-5 and IL-13, two cytokines which are intimately linked to AD pathogenesis [51, 52] . In keratinocytes, IL-9 induces VEGF expression which has been linked to capillary dilatation, dermal edema, and epidermal changes seen in atopic dermatitis [44, 53] . It can be expected that with the advent of biological and targeted therapies in atopic dermatitis, we will soon gain novel insights into the role of T H 9 cells in this common skin disease through translational research [50] .
T H 9 cells in allergic contact dermatitis and allergen-induced delayed type hypersensitivity
Further evidence for an important role of IL-9 in allergic skin inflammation comes from the analysis of allergic contact dermatitis and allergen-induced delayed type hypersensitivity. IL-9 is upregulated in positive skin patch reactions in patients with allergic contact dermatitis [54, 55] . IL-9 expression seems to be a general pathogenetic event in allergic contact dermatitis, as increased levels of IL-9 were found in reactions to a variety of different contact allergens, including metals, drugs, and polymers [54] . In these patch test reactions, both IL-9 gene expression and that of T H 9-associated transcription factors PU.1, ETS-1, IFN regulatory factor 4 (IRF4), and GcN5 were induced, thus suggesting T H 9 cells as prominent source of IL-9 in allergic contact dermatitis. In addition to ACD, IL-9 expression is also upregulated in allergen-induced delayed type hypersensitivity (DTH). In DTH reactions to diphencyprone as well as after intradermal injection of grass pollen in atopic patients, IL-9 was rapidly upregulated within 3 days after challenge but quickly waned again thereafter [6, 56] . Again, these expression kinetics of IL-9 in vivo in humans seem to correspond to those observed in vitro post activation of skin-tropic T H cells. Moreover, levels of IL-9 in the skin correlated with numbers of infiltrating eosinophils indicating a role of IL-9 in their recruitment to the skin [27] .
Whether IL-9 is pathogenic in ACD and cutaneous, DTH has not been directly addressed. However, there is circumstantial evidence that IL-9 may serve as a proinflammatory mediator in ACD. In contact allergic patients, IL-9 expression in both the skin and in peripheral blood mononuclear cells (PBMCs) seems to correlate with the strength of the allergen stimulus. In vitro stimulation of PBMCs with nickel leads to a dose-dependent production of IL-9 in nickel-allergic patients and elevated levels of IL-9 were found in blister fluids of highly positive patch test reactions but not in fluids of other blistering skin conditions [54, 55] . Moreover, PBMCs of allergic patients but not those of tolerant individuals secrete IL-9 after allergen stimulation [57] . In contrast to these findings, a mouse model of ACD showed decreased ear swelling in IL-9 knockout mice and IL-9 was shown to downregulate interferon-γ in vitro, rather suggesting a regulatory role of IL-9 [54] . How these partially conflicting results can be reconciled will have to be addressed in future investigations.
T H 9 cells in psoriasis
Only few reports address the role of IL-9 and T H 9 cells in psoriasis. In human psoriasis, IL-9 expressing CD4
+ T H cells have been found to be increased in lesional skin [2, 44] . However, in these T cells, cytokine co-expression of IL-9 with other T H cell cytokines was not analyzed. Since IL-17 is one of the major cytokines driving psoriatic inflammation and T H 17 cells are able to secrete IL-9 under certain conditions, it remains possible that the IL-9 + cells detected in this study were T H 17 cells rather than T H 9 cells [41] .
Insights into the potential mechanistic role of IL-9 in psoriasis come from a study of K5.hTGF-b1 transgenic mice [53] . In this study, IL-9 induced T H 17-dependent psoriasis-like skin inflammation and angiogenesis. Further, it was shown that IL-9 enhances IL-17 production in human psoriasis patients. These findings are particularly intriguing as they place IL-9 upstream of T H 17-driven inflammation in psoriatic inflammation. Such a scenario awaits further elucidation in additional models of psoriatic inflammation and in translational analysis of psoriasis patients.
T H 9 cells in cutaneous T cell lymphoma IL-9 has long been recognized as an important growth and differentiation factor for transformed lymphoid cells, including malignant T cells [58] [59] [60] [61] . In addition, IL-9 is also capable of modulating the inflammatory microenvironment of lymphoid tumors [62] . In a recent study in cutaneous T cell lymphoma (CTCL), IL-9 has now been linked to the pathogenesis of mycosis fungoides (MF), the most common form of CTCL [63] . Lesional skin of MF patients was enriched with cells expressing IL-9 and IL-9 receptor (IL-9R). IL-9 producing cells belonged to both the malignant and to the infiltrating benign T cell population. In vitro, IL-9 had an anti-apoptotic effect on malignant T cells, which corresponded to the clinical observation that successful therapy of MF patients was associated with decreased numbers of IL-9 and IL-9R expressing cells in lesional skin. These tumorigenic and regulatory properties of IL-9 in MF pathogenesis were finally substantiated in a mouse model where neutralization of IL-9 inhibited tumor growth and improved the reactive T cell response. This regulatory and tumorigenic role of IL-9 in CTCL stands in contrast to the anti-tumor immunity mediated by T H 9 cells in various tumor models [10, [64] [65] [66] , and shows that IL-9 function is highly context-dependent. Howsoever, the well-established function of IL-9 as growth factor of lymphoid tumors and the skin-tropism of T H 9 cells make further investigations of the interrelation of benign and malignant IL-9 secreting T cells in CTCL a promising task.
Involvement of T H 9 cells in other skin pathologies
IL-9 and, thereby, potentially T H 9 cells have been implicated in few additional pathologies that involve the skin, namely systemic sclerosis, alopecia areata, and cutaneous lichen planus. In systemic sclerosis, IL-9 serum levels were elevated and found to correlate with better lung function [67] . In alopecia areata, lesional samples showed upregulated IL-9 gene expression [68] . In lichen patients, IL-9 expression was higher in patients with cutaneous LP as compared to oral LP [69] . All of this data is preliminary and thus prevents any conclusions being drawn about the role of T H 9 cells in these diseases.
Concluding remarks
The skin-homing and skin-resident properties of human T H 9 cells under homeostatic conditions and the many putative target cells of IL-9 residing in the cutaneous compartment make these cells intriguing candidates as key mediators of skin immunity and inflammation [2, 11] . However, much remains to be learned with respect to the cellular identity, the genetic regulation, and the functional role of T H 9 cells, particularly in humans. The future study of these cells will have to address their peculiarities and intricacies, their phenotypic transience, their genetic regulation, the broader repertoire of their effector molecules, and their precise effects on the various targets cells. Based on the superior role of T H 9 cells in mediating anti-tumor immunity in mouse models and the current emergence of successful immunotherapy of cancer patients, T H 9 cells have entered the limelight for novel T cell-based immunotherapies in cancer. Thus, it is an exciting time to further unravel the true identity of this putative novel skin-resident T helper cell subset.
